Form 4: LifeStance Director Sells 92,001 Shares Under 10b5-1 Plan

LifeStance Health Group Director Robert Bessler reported multiple sales of common stock totaling 92,001 shares in December 2025 under a Rule 10b5-1 plan.

Summary

• Director Robert Bessler reported the sale of 92,001 shares of LifeStance Health Group, Inc. common stock across four transactions in December 2025.
• On December 12, 2025, 39,815 shares were sold indirectly through Vitthal LLC at a weighted average price of $7.01 per share, with prices ranging from $7.00 to $7.045.
• Also on December 12, 2025, an additional 39,815 shares were sold indirectly through Shama LLC at a weighted average price of $7.01 per share, within the same price range.
• On December 15, 2025, 6,186 shares were sold indirectly through Vitthal LLC at a weighted average price of $7.00 per share, with prices ranging from $7.00 to $7.01.
• Concurrently on December 15, 2025, 6,185 shares were sold indirectly through Shama LLC at a weighted average price of $7.00 per share, within the same price range.
• All reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• Following these transactions, Robert Bessler's indirect beneficial ownership includes 1,375,989 shares through Vitthal LLC, 1,492,790 shares through Shama LLC, and 36,363 shares through Alpine Glow Capital, in addition to 57,619 shares held directly.

Sentiment

Score: 3

Explanation: Director Robert Bessler reported significant sales of common stock. While these transactions were made pursuant to a Rule 10b5-1 plan, which mitigates some of the negative implications, insider selling is generally viewed with caution by the market.

Positives

• The reported sales were executed under a Rule 10b5-1 plan, indicating that the transactions were pre-scheduled and not necessarily based on immediate, non-public information.

Negatives

• A director selling a significant number of shares (92,001 shares) can be interpreted by the market as a potential lack of strong conviction in the company's near-term prospects or a desire for diversification.

Future Outlook

This filing is a report of insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This insider transaction report reflects a director's personal trading activity and does not directly provide insights into broader industry trends or competitive landscape. However, significant insider selling across the healthcare services sector could indicate a general cautious outlook, though this single filing is specific to LifeStance Health Group.

Stakeholder Impact

• Shareholders may perceive the director's sales as a negative signal, potentially influencing investor sentiment and the company's stock price.

Key Dates

Recommendation

The director's sale of shares, even under a Rule 10b5-1 plan, can signal a lack of strong conviction or a desire to diversify. However, without additional fundamental analysis of LifeStance Health Group, Inc., a 'hold' recommendation is prudent, advising investors to monitor future developments and company performance.

Keywords

LifeStance Health Group, LFST, Robert Bessler, Director, Stock Sale, Insider Trading, Form 4, Equity Transaction, 10b5-1 Plan